MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Cindy Chee, PharmD
Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Harold J. Burstein, MD, PhD
Institute Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Susan Halabi, PhD
Professor with Tenure
Department of Biostatistics and Bioinformatics
Duke University Medical Center
Durham, North Carolina

Philip C. Hoffman, MD
Professor of Medicine
The University of Chicago
Section of Hematology/Oncology
Department of Medicine
Chicago, Illinois

Grzegorz S. Nowakowski, MD
Associate Professor of Medicine and Oncology
Mayo Clinic Rochester
Rochester, Minnesota

Courtney J. Preusse, MA
(Consumer Representative)
Senior Research Administrator and CLIA Operations Director
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Alice T. Shaw, MD, PhD
Director
Center for Thoracic Cancers
Massachusetts General Hospital
Boston, Massachusetts

Thomas S. Uldrick, MD, MS
(Acting Chairperson)
Clinical Director
HIV & AIDS Malignancy Branch
Center for Cancer Research
National Cancer Institute
National Institutes of Health (NIH)
Bethesda, Maryland
ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Non-Voting)

Phuong Khanh (P.K.) Morrow, MD, FACP
(Industry Representative)
Global Product General Manager
Translational Sciences
Amgen
Thousand Oaks, California

TEMPORARY MEMBERS (Voting)

Ronald M. Bukowski, MD
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Bukowski Consulting, LLC
Highland Heights, Ohio

Richard D. Lumley, MS, EdD
(Patient Representative)
Kansas City, Missouri

Lance C. Pagliaro, MD
Professor of Oncology
Mayo Clinic College of Medicine and Science
Senior Associate Consultant
Division of Medical Oncology
Department of Oncology
Mayo Clinic
Rochester, Minnesota

Bruce Redman, DO
Professor of Medicine
Department of Internal Medicine
Division of Hematology/Oncology
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan

Ramaprasad Srinivasan, MD, PhD
Investigator and Head
Molecular Cancer Therapeutics Section
Urologic Oncology Branch
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, Maryland

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD
Director, Oncology Center of Excellence &
Acting Director
Office of Hematology and Oncology Products (OHOP)
Office of New Drugs (OND), CDER, FDA

Julia Beaver, MD
Acting Director
Division of Oncology Products 1 (DOP1)
OHOP, OND, CDER, FDA
FDA PARTICIPANTS (Non-Voting) (cont.)

V. Ellen Maher, MD  
Clinical Team Leader  
DOP1, OHOP, OND, CDER, FDA

Sundeep Agrawal, MD  
Clinical Reviewer  
DOP1, OHOP, OND, CDER, FDA

Laura Fernandes, PhD  
Statistician  
Division of Biometrics V  
Office of Biostatistics  
Office of Translational Sciences, CDER, FDA

James Xu, MD  
Clinical Reviewer  
DOP1, OHOP, OND, CDER, FDA